Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) and Ainos (OTCMKTS:AIMD – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Institutional & Insider Ownership 24.9% of Verrica Pharmaceuticals shares are […]
BML Capital Management LLC acquired a new position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,110,605 shares of the company’s stock, valued at approximately $3,054,000. Verrica Pharmaceuticals accounts for approximately 2.9% of BML Capital Management […]
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) – Analysts at Brookline Capital Management lowered their Q2 2023 earnings estimates for shares of Verrica Pharmaceuticals in a report released on Tuesday, May 9th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from […]
Should You Buy or Sell Verrica Pharmaceuticals Stock? Get The Latest VRCA Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 587,500 shares, an increase of 94.8% from the March 15th total of 301,600 shares. Currently, 2.4% of the shares of the company are short […]